BIOM-02. IDENTIFYING MGMT ALTERATIONS AS BIOMARKERS OF SURVIVAL IN LUNG ADENOCARCINOMA WITH BRAIN METASTASES

EGFR-mutant lung adenocarcinomas (EGFRm-LUAD) have a higher risk of developing brain metastases (BM) compared to non-EGFR-mutant tumors. BM development has significant prognostic impact and leads to poorer patient survival. MGMT promoter methylation is known to determine response to therapy in other...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Autores principales: Mamatjan, Yasin, Zuccato, Jeffrey, Moraes, Fabio, Cabanero, Michael, Shali, Wumairehan, Weiss, Jessica, Tsao, Ming, Aldape, Kenneth, Shepherd, Frances, Zadeh, Gelareh
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2020
Materias:
Biomarkers
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650414/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.002
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares